Biotech Values

[jaybird249]

PATH Migraine NDA submission August 29

PATH has a 4.5 MM float, $70 MM market cap and $32 MM cash.
PATH has a very promising Migrine treatment. It is just as effective and safer than the inhaled drug being developed by MAPP, which has a $400 MM market cap.

For folks looking for a short term rebound play PATH could go higher very quickly.

PATH was in the $7 - $ range until a few days ago but dropped to $3.30 at the low but bounced back to $4.85 Friday. The drop was totally irrational, they announced a financing facility that could be used in the future, but have not issued one new share.